About: EFPIA
Does fast-track drugs approval in EU run too fast?
More than two years after its launch, the EU's fast-track approval process for marketing new drugs, called PRIME, is broadly welcomed by patients and industry, walking the fine line between patients' safety and expediency, and between the need to foster innovation and remaining abuse-proof.
Drug industry reacts to Oxfam’s allegations of tax-dodging
Four of the world’s biggest pharma companies appear to hide their profits in tax havens, according to a report published by Oxfam on Tuesday (18 September). Businesses said they are in the clear.
EFPIA President: Next EU Commission should prioritise competitiveness in pharma innovation
The next European Commission should focus on the bloc’s role in the global context of innovation, as China is “decisive” about creating a reliable framework for intellectual property and connecting biotech start-ups and digital companies, EFPIA’s President Stefan Oschmann told EURACTIV.com in an interview.
Time to end fragmentation of EU healthcare, experts say
Experts are asking for a more collaborative approach in EU healthcare and greater involvement of the European Commission in order to face rising challenges and put patients at the core of decision-making.
Pharma boss: Incentives based on outcomes will optimise EU healthcare
An outcomes-based approach for incentives in the pharmaceutical sector would help optimise the entire healthcare systems, Nathalie Moll told EURACTIV.com in an interview.
Celgene boss: Chronic diseases will bankrupt Europe if incentives are dropped
Alzheimers, diabetes, cancer and other non-communicable diseases will bankrupt Europe if we don’t keep the incentive frameworks alive and well, Mark Alles told EURACTIV.com in an interview.
New Commission study fuels generic drugs industry ‘manufacturing dispute’
The European Commission launched on Thursday (12 October) a public consultation on supplementary protection certificates for pharmaceutical products and the so-called Bolar patent research exemption.
Pharma boss: Targeting drugs won’t make healthcare systems more sustainable
“Salami-slicing” the cost of medicines, which represent almost one-fifth of health system budgets and are subject to rigorous value assessments, won’t make healthcare systems more sustainable in the future, Nathalie Moll told EURACTIV.com in an interview.
Pharma firms and consumer groups united over EMA relocation
EU leaders should make a patient-oriented decision on the relocation of the European Medicines Agency (EMA) from London and ensure “minimal disruption”, according to the pharmaceutical industry and consumer groups.
Big pharma complains about French law pushing cheap eye drug
Europe's pharmaceuticals industry said on Tuesday (1 September) it had filed a complaint with the European Commission against a French law promoting the use of Roche's cancer drug Avastin as an alternative to more expensive eye treatments.